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Case Report
Right Atrial Pacemaker Lead Thrombosis
Incidentally Detected by Transesophageal
Echocardiography
Damir Fabijani}, Lovel Giunio, Marija Vuji~i}, Ivica Vukovi}, Ratko Ermacora and Neboj{a Kne`evi}
Department of Medicine, Division of Cardiology, University Hospital »Split«, Split, Croatia
A B S T R A C T
In a 62-year-old man with permanent atrial fibrillation and recurrent stroke, a large right atrial thrombus at-
tached to a permanent pacemaker lead was incidentally identified by transesophageal echocardiography. Surgical
treatment, recommended because of the large dimensions of the mass, was refused by the patient, and thrombus was
successfully dissolved by anticoagulant treatment. Pathogenesis of pacemaker lead thrombosis, clinical implications,
diagnostic and therapeutic options are discussed.
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Introduction
Pacemaker lead induced venous thrombosis is a
well-known phenomenon that occurs in approximately
30–45% of patients after implantation of a permanent
transvenous pacemaker1. However, development of right-
heart thrombosis in the presence of permanent pace-
maker leads has been rarely described. We report a case
of a large right atrial thrombus attached to a pacemaker
lead incidentally diagnosed by transesophageal echo-
cardiography (TEE).
Patient and Methods
A 62-year old man had an echocardiographic exami-
nation done four weeks after the recurrence of an ische-
mic stroke. He had been treated because of arterial hy-
pertension, ischemic cardiomyopathy, and permanent
atrial fibrillation. A single-chamber pacemaker (Med-
tronic SPECTRAX S) with steroid eluting unipolar
transvenous lead with silicone insulation was implan-
ted, because of symptomatic bradyarrhythmia, thirteen
years ago. CT of the brain confirmed several smaller
ischemic cerebral insults in the left parietal, right occip-
ital and temporal region. The patient was receiving as-
pirin 100 mg daily, as well as antihypertensive therapy.
Clinical and laboratory parameters (including coagula-
tion parameters) were within normal limits. The elec-
trocardiogram confirmed atrial fibrillation and normal
function of the pacemaker in the VVI mode. Transtho-
racic echocardiogram (Vivid 3, General Electric, Mil-
waukee, WI, USA) with a 2.5 to 3.5 MHz ultrasound
transducer demonstrated increased left atrial diameter
(LA = 46 mm) as well as a reduced left ventricular sys-
tolic function (LVEF = 45%). A mobile mass was seen in
the right atrium, but its echocardiographic evaluation
was difficult because of the patient’s obesity. TEE using
a 5-MHz multiplane imaging transducer, which was
performed owing to poor transthoracic echocardiogra-
phic images and inability to exclude an intracardiac em-
bolic source showed a large thrombus (25  21 mm) at-
tached to the atrial segment of the pacemaker lead
(Figure 1). The thrombotic mass did not propagate
through tricuspide orifice, and there were no sign of
acute or chronic right ventricular inflow or outflow ob-
struction. A spontaneous echocontrast in the left atrium
and left atrial appendage, as well as reduced emptying
flow velocity of left atrial appendage (0.22 m/s) was de-
tected. The superior vena cava was free of thrombus. No
other intracardiac masses were found. TEE examina-
tion with bubble contrast study (0.9% saline) and Val-
salva maneuvre did not show intracardiac shunt on the
atrial and/or ventricular level. Other intracardiac mas-
ses, atrial or ventricular septal defect were not found.
Three-dimensional ultrasonography with Doppler study
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of the carotid arteries that is a reliable diagnostic me-
thod in evaluating atherosclerotic lesions of carotid ar-
teries 2, as well as a TEE imaging of the thoracic aorta
did not show plaques that could be potential sources of
embolization. Lung scintigraphy by technetium 99 did
not reveal any perfusion defects.
Because of the thrombus size and mobility surgical
removal of thrombus was recommended to our patient,
but was refused. Thrombolytic therapy was not admin-
istered because of the recent stroke, and the patient was
treated with low-molecular weight heparin followed by
per os anticoagulant therapy with target INR within the
range of 2.5 to 3.5. Echocardiographic follow-up con-
firmed gradual dissolution of the thrombus after 6
weeks. After complete resolution of thrombus chronic
anticoagulant therapy was continued according to Euro-
pean Society of Cardiology (ESC) guidelines for perma-
nent atrial fibrillation with recommended INR between
2.0 and 3.0.
Discussion
Serious thrombotic and embolic complications are re-
ported to occur in 0.6–3.5 % of patients with permanent
transvenous pacing leads1. Right atrial pacemaker lead
thrombosis has been less frequently described, present-
ing either as an incidental echocardiographic finding3 or
by symptoms of right-sided heart failure4, obstruction or
embolization of pulmonary artery5.
Several mechanisms have been postulated in the
pathogenesis of pacemaker lead induced thrombosis6.
The long-term residence of permanent pacemaker leads
may act as a continous nidus for the formation of throm-
bus. In cases of dual-chamber pacing multiple pace-
maker wires increase the total surface area of foreign
material at risk for thrombus formation. Pacemaker
leads may produce a foreign-body-type reaction with
subsequent inflammation and fibrosis along the course
of the wire, and this may lead to thrombus propagation
along the pacing lead. Furthermore, congestive heart
failure, hypercoagulable states such as antithrombin
III, protein C and S deficiencies, thrombocytosis, malig-
nancies, and possibly pacemaker lead material itself,
may predispose to thrombosis7–9. It has been shown that
pacemaker leads with different types of insulation have
various thrombogenicity. Namely, thrombogenicity of
polyurethane leads may be lower than that of silicone
leads9.
Intracardiac, generally right atrial lead thrombosis
is more dangerous and difficult to manage. The hemo-
dynamic significance of the intracardiac clot depends on
its size, ranging from one to several centimeters in di-
ameter, and location10. Atrial arrhythmias can occur if
the sinoatrial area is involved. Similar to atrial myxo-
mas, intracardiac thrombus may cause functional tri-
cuspid stenosis or insufficiency, and should be conside-
red when refractory right ventricular failure is present4.
Systemic embolization can be related with perma-
nent pacing in several ways. Paradoxical embolus can
result in the presence of an established or transient
intracardiac right-to-left shunt (i.e. latent foramen
ovale)11. Transvenous pacemaker leads may be placed
unintentionally into the left ventricle via a patent fora-
men ovale or through atrial septal defect, resulting in
thromboembolic complications, primarily embolic stro-
ke12,13. Finally, patients in a VVI pacing mode have a
higher incidence of paroxysmal and permanent atrial fi-
brillation, which independently predisposes to embolic
events. Patients with VVI pacing mode have a signifi-
cantly higher incidence of reduced left atrial appendage
function than patients with atrioventricular sequential
(VDD, DDD) pacing14–16.
D. Fabijani} et al.: Pacemaker Lead Thrombosis, Coll. Antropol. 29 (2005) 1: 159–161
160
Fig. 1. Transesophageal echocardiographic image: large thrombus (thick arrow) attached to the atrial portion of the
pacemaker lead (thin arrow). LA = left atrium; RA = right atrium; LV = left ventricle; RV = right ventricle.
U:\coll-antropolo\coll-antro-1-2005\fabijanic.vp
17. lipanj 2005 08:24:20
Plate: 2 of 3
Color profile: Disabled
Black  150 lpi at 45 degrees
Despite accepted clinical guidelines for the stroke
prevention in patients with atrial fibrillation, our pa-
tient was treated only with aspirin 100 mg daily. Carls-
son et al.17 have reported that only 28% of the patients
with permanent pacemaker and atrial fibrillation were
anticoagulated; only 10.8% of those who were not anti-
coagulated had contraindications to the therapy. They
concluded that the majority of pacemaker patients with
atrial fibrillation, for whom anticoagulation is indi-
cated, failed to receive it. Those caring for these patients
are urged to ensure its much widely use.
In spite of the considerable size of the thrombus our
patient was asymptomatic, and thrombosis of the pace-
maker lead was detected incidentally. The position of
the pacemaker lead in the right ventricle was confirmed
by TEE, and the existence of a right-to-left shunt was
excluded by contrast echocardiography. Therefore, the
pacemaker lead thrombus could not be related with the
previous ischemic strokes in our patient. Probable so-
urces of recurrent stroke were thromboemboli due to
permanent atrial fibrillation, as suggested by the re-
duced emptying flow velocity of the left atrial append-
age (0.22 m/s), the spontaneous echocontrast in left
atrium and left atrial appendage defined as a 3+ = mod-
erate (dense swirling pattern during the entire cardiac
cycle), according the criteria of Fatkin et al.18. Our pa-
tient was treated with a low-molecular weight heparin
and gradual dissolution of the thrombotic formation was
documented by echocardiography. Chronic anticoagu-
lant therapy with warfarin was administered because of
the increased risk of a repeated ischemic stroke.
We recommend that all patients with permanent
pacemakers who have an increased risk for lead throm-
bosis, including those with congestive heart failure,
hypercoagulable states, and immobilization, should be
considered for systemic anticoagulation. However, be-
cause a case of the pacemaker lead thrombosis with
massive pulmonary embolism within 12 hours after a
permanent transvenous pacemaker implantation has
been reported19, anticoagulant therapy should be star-
ted early.
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TROMB NA VODI^U ELEKTROSTIMULATORA SRCA U DESNOM ATRIJU – SLU^AJAN NALAZ
TRANSEZOFAGUSNOM EHOKARDIOGRAFIJOM
S A @ E T A K
U 62-godi{njeg mu{karca s permanentnom fibrilacijom atrija i ponavljaju}im mo`danim infarktom, transezofa-
gusnom ehokardiografijom je u desnom atriju na elektrodi trajnog elektrostimulatora srca prikazan ve}i ugru{ak.
Zbog veli~ine ugru{ka preporu~en je operativni zahvat kojeg je bolesnik odbio, pa je ugru{ak otopljen primjenom
antikoagulansa. U radu se razmatra patogeneza ugru{ka na elektrodi elektrostimulatora, klini~ke posljedice, di-
jagnosti~ke i terapijske mogu}nosti.
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